SCHEMBL20371015

SCHEMBL20371015

Cc1ccc(B(O)O)cc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.57
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
FFAR4 Q5NUL3 2/20 0.46
ENPP2 Q13822 2/20 0.45
FFAR1 O14842 1/20 0.44
STAT3 P40763 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PTPN1 P18031 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29958132 1.00 LIPE (0.57) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL1163386 0.88 LIPE (0.57) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL29954144 0.88 LIPE (0.57) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL16320521 0.85 LIPE (0.57) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL4329673 0.83 SMPD1 (0.56) LIPEMAPK1RXRAENPP2HTT
SCHEMBL906202 0.83 NPC1 (0.57) LIPEENPP2SMN1; SMN2
SCHEMBL29956215 0.83 NPC1 (0.57) LIPEENPP2SMN1; SMN2
SCHEMBL25526392 0.83 MAPT (0.47) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL28606699 0.83 LIPE (0.68) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL544428 0.81 LIPE (0.53) LIPEMAPTRXRARXRBENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
CN-117062813-A Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2023-11-14 CN disclosed
US-20230151159-A1 COMPOUND FOR FORMING HARDMASK, HARDMASK COMPOSITION INCLUDING THE COMPOUND, AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE HARDMASK COMPOSITION SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-05-18 US disclosed
US-20190327974-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2019-10-31 US disclosed
WO-2018127928-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2018-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190327974-A1 SYNERGISTS FOR IMPROVED PESTICIDES BCHE, DDT, DBF4 LIPE 1435/4885MAPT 2085/4885MAPK1 4199/4885
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A LIPE 2103/4885MAPT 138/4885MAPK1 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.